Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test

This article was originally published in The Gray Sheet

Executive Summary

Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery
Advertisement

Related Content

Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test
Washington Roundup, February 2013
Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies
Utility Before Profitability: The Evolving Evidence Paradigm For Molecular Diagnostics
People In Brief
Financings In Brief
Financings In Brief
Ovarian cancer test

Topics

Advertisement
UsernamePublicRestriction

Register

MT028618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel